We expect HCG to deliver a healthy Ebitda CAGR of 19% over FY2018-20 and valuations are now reasonable at 13X FY2020e Ebitda. Upgrade to BUY with a target price of Rs 270 (versus Rs 290 earlier).

KKR will buy an equity stake of as much as 54% in HCG from CVC at a purchase price of 445 rupees per share, Healthcare Global said in a statement to the exchanges late Sunday. KKR will also ...

HealthCare Global (HCG) poised for growth with expansion plans, acquisitions, and KKR stake acquisition driving revenue and EBITDA growth.

Private equity giant KKR has signed a definitive agreement to pick up a controlling stake in cancer care hospital chain Healthcare Global Enterprises (HCG) from CVC Asia V for $400 million ...